Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma 7Lymphoma, Follicular 6Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma, Mantle-Cell 3Recurrence 2Advanced Malignancies 2Unresectable or Metastatic Solid Tumors 1Pancreatic Neoplasms 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1B-Cell Malignancies 1

Interventions

Peripheral Blood Stem Cell Transplantation 32fludarabine phosphate 29Cyclophosphamide 26Whole-Body Irradiation 21Cyclosporine 20Busulfan 20Mycophenolic Acid 19Tacrolimus 16Antilymphocyte Serum 14Methotrexate 13romidepsin 12Etoposide 12Filgrastim 11Melphalan 9Psychiatric Rehabilitation 8Methylprednisolone 8Dexamethasone 8Bexarotene 8Vorinostat 7Flow Cytometry 7Therapeutics 6Radiotherapy 6Calcium Dobesilate 6Brentuximab Vedotin 6Bortezomib 6Alemtuzumab 6sargramostim 5fludarabine 5denileukin diftitox 5Polymerase Chain Reaction 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, T-Cell, Cutaneous × parsaclisib × Clear all
NCT04774068 2025-01-17

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
5 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡